Prescription drug · NDA
Rizafilm (rizatriptan benzoate) NDC 50090-8038
Rizatriptan benzoate 10 mg/1 · Film · Oral · A-S Medication Solutions
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50090-8038-0 | 50090803800 | 3 FILM in 1 BOTTLE (50090-8038-0)Marketed from Aug 26, 2026 | |
| 50090-8038-1 | 50090803801 | 9 FILM in 1 BOTTLE (50090-8038-1)Marketed from Aug 26, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Rizafilm
- Generic name (nonproprietary)
- rizatriptan benzoate
- Active ingredients
- Rizatriptan benzoate — 10 mg/1
- Dosage form
- Film
- Route
- Oral
- Labeler
- A-S Medication Solutions
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 205394
- Marketing start
- Listing expires
- Other FDA classes
- Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
- Identifiers
- Product ID 50090-8038_07cd6b0a-291d-4a45-8f01-a2d68239623cSPL ID 07cd6b0a-291d-4a45-8f01-a2d68239623cSPL set ID 8e36b946-cf2a-44d9-9ba7-4385cfe6b360RxCUI 2634482, 2672955UNII WR978S7QHH
- Pharmacologic class
- Serotonin-1b and Serotonin-1d Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450090803800followed by a unit qualifier and the quantityPackage 50090-8038-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
RizaFilm™ is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age. Limitations of Use RizaFilm should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with RizaFilm, the diagnosis of migraine should be reconsidered before RizaFilm is administered to treat any subsequent attacks. RizaFilm is not indicated for the preventive treatment of migraine. Safety and effectiveness of RizaFilm have not been established for cluster headache. RizaFilm is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migrai…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 205394
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.